Metastatic Colorectal Cancer Gene Expression and Clinical Outcomes from TCGA

A clinical and gene expression analysis of 251 patients with metastatic colorectal cancer, comparing left-sided colon cancer (LSCC) and rectal cancer (RC). The study, authored by N. N. Semenov and last updated in April 2026, uses data from 155 LSCC and 96 RC patients for clinical analysis and mRNA expression data from 153 LSCC and 41 RC patients sourced from The Cancer Genome Atlas (TCGA).

Use Cases

• Comparing long-term clinical outcomes between metastatic rectal cancer and left-sided colon cancer based on patient cohort data.
• Analyzing differential gene expression (e.g., EBI3, IL-17A, SOCS1) associated with chemotherapy response.
• Investigating VEGF pathway gene expression (VEGF-A, VEGF-D, KDR-VEGFR2) in relation to anti-VEGF therapy sensitivity.

Strengths

• Includes clinical data from 251 patients with synchronous metastases.
• Integrates mRNA expression data from The Cancer Genome Atlas (TCGA) for 194 patients.
• Explicitly compares two distinct colorectal cancer subtypes (LSCC and RC).

Limitations

• Row count for the gene expression data is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small (26.3 KB), indicating limited scope.

Provenance

Source

The Cancer Genome Atlas (TCGA) and a clinical patient cohort.

Collection Method

Clinical analysis of patient records and bioinformatics analysis of TCGA mRNA expression data.

Time Range

null

Freshness

Last updated 2026-04-15 04:36:54; freshness should be verified.

Geography

null